Dihexa vs NAD+
Emerging vs Extensively Studied
compatible Complementary mechanisms for cellular health.
Molecular Data
Dihexa NAD+
Weight 504.7 Da 663.43 Da
Half-life 8-12 days 1-4 hours (intracellular)
Type Modified oligopeptide Coenzyme
Key Benefits
Dihexa
01 Dramatic synaptogenesis promotion
02 10 million times more potent than BDNF
03 Cognitive enhancement and memory improvement
04 Neuroprotection and potential neuroregeneration
05 Applications for Alzheimer's, TBI, age-related cognitive decline
06 Oral bioavailability
NAD+
01 Restores mitochondrial function and ATP synthesis
02 Enhances glucose and fat metabolism
03 Improves oxygen utilization and endurance
04 Activates DNA repair mechanisms
05 Supports longevity pathways via sirtuins
06 Improves mental clarity and focus
Dosing Protocols
Dihexa
8-10mg oral or 2-5mg injectable (0.5mg/kg based on research) / Once daily in the morning
Research protocol 0.5mg/kg daily Daily or 3x weekly
Standard injectable 2-5mg total 1x daily
NAD+
IV: 250-1000mg; IM/SubQ: 100-500mg; Intranasal: 25-50mg; Oral precursors: 100-500mg NMN/NR / IV: 1-2x weekly; IM/SubQ: 2-3x weekly; Intranasal: 1-2x daily; Oral: daily
IV Infusion 250-1000mg 1-2x weekly
IM/SubQ 100-500mg 2-3x weekly
Side Effects
Dihexa
Headaches (most frequent side effect)
Anxiety or overstimulation
Sleep disruption when dosed late in day
Mental clarity increase
NAD+
Mild flushing during IV infusion
Temporary nausea
Contraindications
Not FDA approved - research compound only
Theoretical cancer risk via c-Met activation
Cancer history (avoid due to c-Met pathway)
Pregnancy or breastfeeding
No long-term human safety data
IV administration requires medical supervision
Avoid alcohol during treatment
Maintain consistent dosing schedule
Research Evidence
Dihexa NAD+
Status Emerging Extensively Studied
References 3 studies 4 studies
Latest 2024 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.